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Caspase-3Enteroviridae such as coxsackievirus are important infectious agents causing viral heart diseases. Viral
protease 2A (2Apro) initiates the virus life cycle, and is an excellent target for developing antiviral drugs.
Here, to evaluate the validity of the 2Apro as a proper therapeutic target, and based on the existing
information and molecular dynamics, a 16-mer peptide was designed to speciﬁcally target the active site of
protease 2Apro in order to block the activity of CVB3 2Apro. We showed that the peptide could compete with
endogenous substrate in a concentration-dependent manner. Further, we established a HeLa cell line that
expressed 2Apro. Expression of 2Apro resulted in signiﬁcant morphological alteration and eventual cell death.
Western blot and viability assay showed that the 16-mer peptide (200 μg/ml) could signiﬁcantly block 2Apro
activity and its cytotoxic effect. Future modiﬁcation of the 16-mer peptide can improve its afﬁnity for 2Apro
and therefore develop effective antiviral drug.udi).
script.
ll rights reserved.© 2009 Elsevier Inc. All rights reserved.Introduction
Coxsackievirus B3 (CVB3) is considered as the most important
infectious agent that can cause severe heart complications. CVB3 is
associated with both acute and chronic forms of myocarditis
(inﬂammation of the myocardium), a life threatening disease (Reyes
and Lerner, 1985; Woodruff, 1980). Chronic forms of this disease may
lead to dilated cardiomyopathy (DCM), for which the only available
and effective treatment is the highly cost heart transplantation
procedure. Entroviruses, in general, and CVB3, in particular, are
responsible for causing up to 30–45% of acute forms of myocarditis
and 25% of DCM (Bowles et al., 1986; Frisk et al., 1984). In an infected
cardiomyocyte, cleavage of dystrophin by viral 2Apro is considered an
important mechanism for CVB3-induced cardiac injury (Badorrf et al.,
1999). CVB3 infection is also associated with programmed cell deathand apoptosis in myocardial tissue (Goldstaub et al., 2000; Olivetti
et al., 1997).
CVB3 is a picornavirus, a family of small positive-stranded RNA
viruses associated with a large variety of human and animal diseases.
Following virus entry, viral RNAs are translated, and newly synthe-
sized viral proteins are released within the cytoplasm of infected host
as large a polyprotein, which will be then processed and further
cleaved by virus-speciﬁc protease 2A and 3C to generate mature
structural and nonstructural viral proteins (Krausslich and Wimmer,
1988; Skern and Liebig, 1994). Viral replication depends on this
proteolytic cleavage. Although the newly synthesized viral polypro-
tein is processed mainly by 3Cpro, the primary cleavage event
separating the structural protein precursor from the nonstructural
one is performed by 2Apro (Hanecak et al., 1982; Toyoda et al., 1986).
Viral protease 2A is a multifunctional chymotrypsin-like cysteine
proteinase that catalyzes the cleavage of the viral polyprotien at a
tyrosine-glycine pair between the C-terminus of VP1 and its own N-
terminus (Rueckert, 1996; Toyoda et al., 1986). Both 2Apro and 3Cpro
are also responsible for the cleavage of the other cellular proteins such
as the eukaryotic Initiation Factor-4G (eIF4G) and the cytoplasmic
protein dystrophin. Cleave of eIF4G (formerly known as p220) leads
Fig. 2. Cells were induced by 300 ng/ml Dox (Sigma) for expression of 2Apro and
48 hours later, induced Hygromycin resistant clones were collected and total RNA
extraction was done and extracted RNA reverse-transcribed and ampliﬁed using gene
speciﬁc primers for 2Apro and β-actin. An 840 bp RT–PCR product corresponding to the
ampliﬁed β-actin (internal control) fragment was observed in all clones. In contrast, the
500 bp RT–PCR product corresponding to the ampliﬁed 2Apro fragment was only
observed in positive clones (positive clones have been shown in this ﬁgure). Clones #4
and #5 were selected for further analyses. M: 1 kb DNA ladder, Fermentas.
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et al., 1991; Seipelt et al., 2000; Ventoso et al., 1998). Another protein
of the cellular translation apparatus, poly-ADP-ribose-polymerase
(PARP), is also cleaved by 2Apro and 3Cpro (Calandria et al., 2004).
Due to the unique protein structure and essential role played by
2Apro and 3Cpro in viral replication and disease progression, they have
been considered as potential therapeutic targets to block virus
replication and virus-induced cell injury (Krausslich and Wimmer,
1988; Sablina and Antonov, 1991). Despite considerable efforts in
recent years, no promising antiviral compound for CVB3-induced
heart diseases has been developed. In the present study the cleavage
motif of CVB3 2Apro substrate was used to generate a potent
competitor peptide that potentially competes with and blocks 2Apro
activity and subsequent viral replication.
In order to further study the effect of the newly designed peptide
on 2Apro activity, we used a tetracycline-dependent (Tet-on)
expression HeLa cell line, in which the expression of viral 2Apro was
conditionally controlled. Such tightly controlled system provided us
with the proper tool to monitor the direct interaction between
conditionally overexpressed viral 2A protease and the synthesized
competitive peptide in a timely manner.
Results
In vitro activity of the puriﬁed 2Apro
To ensure the integrity of the puriﬁed 2Apro and the efﬁciency of
the cloning and transformation, 2Apro gene was approved by
sequencing in pET22b. After puriﬁcation, to assay the activity of the
2Apro, the cleavage of eIF4G, as the speciﬁc substrate of 2Apro and a
component of eIF4F, was analyzed. As shown in Fig. 1, addition of the
puriﬁed enzyme resulted in complete cleavage of eIF4G, indicating
that the puriﬁed 2Apro was active.
Isolation of HeLa cell clones expressing coxsackievirus B3 2Apro under the
control of Tet-on expression system
The Tet-On inducible gene expression system provides ready
access to a tightly regulated, high-level gene expression system as
described by (Gossen et al., 1994) with modiﬁcations made by
(Urlinger et al., 2000). In the Tet-On system, expression is activated by
the addition of doxycycline (Dox), a tetracycline derivative, to the
culture medium. This permits gene expression to be tightly regulated
a speciﬁc stimulus (e.g., doxycycline). Unlike other inducible
mammalian expression system, gene regulation in the Tet-on/off
systems is highly speciﬁc, so results are not complicated by pleiotropic
effects or nonspeciﬁc inductions.
A stable double-transformed HeLa Tet-On/2Apro cell was estab-
lished as described in the Material and methods section. After
selection and cell cloning, hygromycin resistant cell clones were
screened for expression of 2Apro by RT–PCR. Two clones, 4 and 5, were
clearly positive in this method (Fig. 2). Dox was added to 80%
conﬂuent double-stable cells as well as noninducible HeLa cells
(Fig. 3a) and 1 day after addition of Dox to selected clones, cells round
up (Fig. 3b, Tet-on HeLa cells), and after 48 hours of incubation less
than 1% of cells remained viable and attached to the culture plate
(Fig. 3c, Tet-on HeLa cells). In the presence of doxycycline, theseFig. 1. Activity of recombinant 2Apro. 10 μg of the recombinant 2Apro incubated with S10(eI
Reactions stopped by addition of sample buffer and were subjected to 7.5% SDS–PAGE and W
marker have been shown in lanes 1 and 5, respectively.clones displayed a high expression of viral 2Apro, PARP protein
cleavage, and an increased level of apoptosis.
Homology modeling and structure prediction
Multiple sequence alignment of CVB3 and HRV2 2Apro revealed
that conserved residues are spread along the whole sequence but N-
terminal regions are the least conserved residues (Maghsoudi et al.,
2008). Judging from such a high sequence homology, a high-quality
3D structure of CVB3 2Apro can be expected in homology modeling. It
is indeed well known that a homology-modeled structure of a target
protein can be accurate enough to be used in a docking study once the
sequence identity between target and template approaches 40%
(Baker and Sali, 2001).
Topology of predicted homology model of CVB3 2Apro
To determine the 3D structure of the protein, an ensemble of 25
model structures was generated. Table 1 presents a comparison
between the accessible surface area (ASA) obtained using HM- and
PHD-derived results. The overall ASA HM structure and PHD derived
ASA are similar. Therefore, the HM-predicted structure is conﬁrmed
by PHD data. The overall tertiary structure of CVB3 2Apro strongly
resembles that of its template HRV2 2Apro. Fig. 4a shows the schematic
representation of a homology model of CVB3 2Apro showing
arrangement of structural elements. The tertiary structure comprises
beta barrel globally. This domain type is common among proteases
and it resembles trypsin-like protease.F4G) at 0 (lane 2), 2 (lane 3), 6 (lane 4), 8 (lane 6), 12 (lane 7), and 24 (lane 8) hours.
estern blot using anti-17CV antibody. Negative control for S10, and molecular weight
Fig. 3.Morphological alteration of stable HeLa cell expressing coxsackievirus B3 2Apro under the control of tet (clone number 5). Phase-contrast microscopy of HeLa cells at different
time points after induction of 2Apro: (a) absence of viral 2Apro (0 hour), (b) 28 hours after induction of viral 2Apro expression, and (c) 48 hours after induction of viral 2Apro
expression. Noninducible HeLa cells were treated with Dox with the same concentration. Dox does not have any nonspeciﬁc effects on the non-inducible cells.
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In order to understand the speciﬁcity of CVB3 2Apro, an oligopep-
tide structurally determined by molecular dynamics was docked into
the substrate binding site. The cleavage site for both HRV2 and CVB4
2Apro corresponding to GRTTLSTR↓GPPRGGPG in human eIF4G
(Lampheaer et al., 1993). We studied to determine whether CVB3
2Apro has the same cleavage site since HRV2 and CVB3 2Apro have a
strong similarity in their active sites. In addition, Wang et al. (1998)
reported that HRV2 2Apro cleaves a peptide corresponding to its own
cleavage site in vitro.
To design inhibitors with great potency against enzymes, substrate
sequence was used. The nomenclature Pn-P1-P1′-Pn′, of substrate or
inhibitor was reported by Lampheaer et al. (1993) with the scissile
peptide bond lying between P1 (Arg) and P1′ (Gly). As shown in
Fig. 4b, among different binding possibilities, this peptide has high
afﬁnity for two amino acids located in the enzyme active site (binding
energy of−402.6 kJ/mol). Such afﬁnity cannot be found at the other
sites. Replacing Arg in P1 with Asp resulted in a signiﬁcant decrease in
afﬁnity for enzyme (data not shown).
Electrostatic complementarities of interacting surfaces are impor-
tant factors for protein-protein interaction. In our previous investi-
gation, we showed that CVB3 2Apro is a negatively charged protein
(Maghsoudi et al., 2008), whichmakes it more possible for a substrate
with positive potential to enter the active site. In Fig. 4c, the global
electrostatic potentials of the residues have been mapped on theTable 1
Comparison of the accessible surface area (ASA) obtained using HM and PHD.
e: exposed, i: intermediate, b: buried.protein surface, which has been found to be a negatively charged
protrusion, symbolized as a red bump. These calculations indicate that
the best ligand–receptor complementary electric ﬁeld appears in one
ligand binding site, which was conﬁrmed by HEX output as the most
stable one as well.
In a separate investigation, the inhibitory effect of this peptide on
2Apro–substrate (eIF4G) was determined experimentally by an in vitro
cleavage assay. As shown in Fig. 4d, this peptide could signiﬁcantly
decrease eIF4G cleavage by viral 2Apro.
In addition, Western blot analysis has shown that the proteases 2A
can cleavage the poly-ADP-ribose-polymerase (PARP). The cleavage is
partially blocked by 50 μg/ml of designed peptide, suggesting an
inhibitory effect of the synthesized peptide on viral 2Apro activity
(Fig. 5). Results from the cell viability assay (MTT) have also shown
that at the concentration of 100 μg/ml, our synthesized peptide can
completely blocks 2Apro activity and subsequent cell death whereas
the scrambled peptide (Arg in P1 was replaced by Asp in its sequence)
could not inhibit cell death signiﬁcantly (Fig. 6). The docking of 2Apro-
substrate along with our experimental data would thus support a
direct cleavage of eIF4G that continues to be the subject of much
debate (Bovee et al., 1998).
Discussion
Coxsackievirus B3 (CVB3) is the most common cause of inﬂam-
matory heart diseases and the subsequent end-stage cardiomyopathy
Fig. 4. (a) The 3D structure of CVB3 2A pro. Ribbon diagram of the overall structure was generated using the Swiss pdb viewer program. Helix and sheet are shown in red and yellow,
respectively. (b) A model of substrate binding in CVB3 2Apro. Enzyme, active site and substrate (16-mer peptide) are donated by white, yellow, and dark red colors, respectively. The
three important amino acids in active site that interact with substrate are shown by light red color. (c) Electrostatic complementarities between CVB3 2Apro and an oligopeptide
substrate. Enzyme and substrate characterized by negative and positive potentials highlighted by red and blue colures, respectively. (d) The inhibitory effect of peptide on 2Apro–
substrate interaction. About 10 μg/ml of the puriﬁed CVB3 2Apro incubated with S10 (eIF4G) in the presence of 0 (lane 1), 1 (lane 2), 3 (lane 3), and 5 mM (lane 4) peptide. After
8 hours, the reaction was stopped by addition of sample buffer and was subjected to 7.5% SDS–PAGE and Western blot analysis using anti-17CV antibody.
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1980). CVB3 genome encodes two proteases, 2A and 3C, which are
responsible for processing the viral polyprotein, and therefore, for
production of all mature viral particles (Krausslich and Wimmer,
1988; Skern and Liebig, 1994). In addition, they are involved in the
cleavage of host cells proteins essential for normal cellular homeo-
stasis and functions such as transcription, translation and cytoskeletal
integrity (Badorrf et al., 1999; Hellen et al., 1991; Seipelt et al., 2000;
Ventoso et al., 1998). Due to their unique protein structures and
essential roles in viral replication, 2A and 3C proteases have been
considered as suitable targets for blocking virus replication and its
destructive effect within the host cell (Krausslich andWimmer, 1988;
Sablina and Antonov, 1991). Considering their crucial roles during
virus life cycle, inhibition of these proteases may be an excellent
strategy to restrain viral replication and resulting detrimental effects
on the heart and other infected organs.
Several compounds targeting 2Apro of polioviruses and rhino-
viruses have been reported including the inhibition of 2Apro by o-
phenanthroline, leupeptin, zVAD.fmk [benzyloxycarbonyl-Val-Ala-
Asp (OMe)-ﬂuoromethylketone] (Deszcz et al., 2006; Konig and
Rosenwirth, 1988). However, their effects are not speciﬁc to viralproteins and may include some host cell proteins as well. One
example is the nonspeciﬁc binding of Z-VAD-fmk or related caspase
inhibitors to nonviral proteases that contain a cysteine in their active
sites like cathepsin B or H (Schotte et al., 1999).
During the last decade, the need for an antiviral drug with no side
effect on host cells normal physiological functions has been
increasing. The main challenge is to design an effective and highly
speciﬁc inhibitor capable of blocking viral replication, preferably
during the early phase of virus life cycle. A rational strategy to develop
a speciﬁc protease inhibitor should be based on the structure and
function of the protease. Unfortunately, no report of the three-
dimensional structure of CVB3 2Apro has been published.We therefore
predicted the 3D structure of CVB3 2Apro based on the comparative
homology modeling. In the absence of a crystal structure, our study
can provide a rational alternative for structure-based drug design. So,
in the present study, we have focused on designing a highly speciﬁc
competitor peptide in an attempt to block the activity of CVB3 2Apro in
a HeLa cell culture model.
To analyze the effect of the synthesized peptide on 2Apro, we used
a tetracycline (Tet)-dependent expression system. This system can
constitute an easy and rapid screening method for identiﬁcation of
Fig. 5. PARP cleavage in HeLa cell line inducibly expressing the 2Apro and the effect of peptide on PARP cleavage. Two clones (number 4 and 5) were selected based on RT–PCR results.
Positive clones of HeLa cells grown in ﬂasks were treated by Dox (300 ng/ml) to express 2Apro, and were then treated with 50 μg/ml of peptide. PARP cleavage was measured by
Western blot analysis using anti-PARP monoclonal antibody.
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sion of viral 2Apro induces apoptosis that is associatedwith cleavage of
caspase-3 and PARP proteins conﬁrming that our Tet/2Apro system
mimics the actual CVB3 infection in a HeLa cell culture. Treatment of
the Tet/2Apro system with our synthetic inhibitor peptide rescued
HeLa cells and blocked cell apoptosis caused by 2Apro. Our results have
shown that 2Apro activity is inhibited more than 60% by 50 μg/ml
peptide; therefore, the peptide is likely to be structurally very similar
to 2Apro substrate and can be effective and speciﬁc tool for inhibiting
of 2Apro action, preventing the apoptotic effect on host cells, and
suggesting an effective and feasible therapeutic approach for viral
myocarditis.Fig. 6. Effect of the 16-mer peptides as well as scrambled peptide on cell viability. HeLa
cell line expressing coxsackievirus B3 2Apro were treated with the synthetic peptides at
the indicated concentration and then HeLa cell viability was determined by MTT assay.
Cell viability is calculated as the percentage of living cells in treated cultures to those in
control cultures. Data are represented as means±SEM of three independent
experiments.There are other approaches to control CVB3 replication, amongst
which are reports on application of siRNA to block its replication
(Yuan et al., 2005; Merl et al., 2005). However, the main challenge for
siRNA is still the problem with the targeted delivery and nonspeciﬁc
bindings (Zhang et al., 2009). Another limitation is that siRNA
targeting CVB3 mRNA strand is probably more effective during the
very early stages of virus replication and is more practical when virus
infection is detected early. The efﬁciency of such approach during the
chronic phase of infection, in which most of the cytotoxic effects
caused by virus in due to the cleavage of host cell proteins by viral
proteases, is a matter of question. Such limitation in siRNA delivery
warrants further investigation to establish inhibitory peptides that are
more speciﬁc in binding to the protein of interest, and easier to
deliver.
In conclusion, this study is a proof of principle that demonstrates a
well-established, tightly controlled and consistent in vitro model for
studying and monitoring the inhibition of viral protease 2A functions
and destructive effects. Furthermore, the observation that our 16-mer
peptide appears to be highly modiﬁable will provide us with
possibilities in the future to improve its structure to achieve a
higher-afﬁnity or a potent noncompetitive and speciﬁc inhibitor for
protease 2A. The ultimate goal is to test the inhibitory peptide in an in
vivo animal model of viral myocarditis.
Materials and methods
Viral RNA preparation
Dulbecco's modiﬁed Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS)was used for growth andmaintenance of
HeLa cells cultures. Subconﬂuent cell cultures were infected with 105
plaque-forming units (PFU) CVB3 in a medium containing 1% fetal
bovine serum. Cell lysates were then collected at 24 hrs post-infection
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RNX solution as described by the manufacturer (Cinagen, Iran).
Brieﬂy, after homogenizing the cells, 1 ml of RNX solution was added
to the tube and incubated at room temperature for 5 min. Chloroform
was added to the solution and centrifuged for 15 min at 12,000 RPM.
The upper phase was then transferred to another tube and an equal
volume of isopropanol was added. The mixture was centrifuged for
15min at 12,000 RPM and the resulting pellet was thenwashed in 70%
ethanol and dissolved in DEPC-treated water.
Construction of expression vector
cDNA that was generated from PCR product of 2Apro was cloned
into pET22b vector, and the direction of cloning was conﬁrmed. For
expression, pET-2Apro recombinant vector was transferred to Escher-
ichia coli BLR(DE3)pLysS strain and IPTG was used to express 2Apro as
described previously (Maghsoudi et al., 2008). Finally, puriﬁcation
was performed by Q-Sepharose column (Pharmacia, Sweden).
The ability of puriﬁed 2Apro to cleave eIF4G, a natural substrate of
2Apro, was assayed on postmitochondrial HeLa cell extracts (S10) that
were obtained as described by Brown and Ehrenfeld (1979). The S10
extract was incubated with 5 μg of puriﬁed 2Apro protein for 2 hours at
37 °C. The reaction was stopped by adding 1/4 volume of 4× sample
buffer (640 mM Tris–HCl pH 6.8, 8% SDS, 20% 2-mercaptoethanol, 40%
glycerol, 4 mM PMSF, and 0.015% bromophenol blue). The samples
were analyzed by Western blotting using a polyclonal antibody
against eIF4G. Production of rabbit antiserum against eIF4G was
carried out as previously described (Maghsoudi et al., 2008).
Generation of stably transformed HeLa cells bearing the CVB3 2Apro gene
The Tet-On system is based on two mutant “reverse” Tet
repressors (rTetRs) that bind to tetO in the presence of doxycycline
(Sigma, USA). These rTetRs have been fused to VP16 AD. The resulting
trans-activators (rtTA) activate transcription from a TRE as a
consequence of doxycycline treatment (Gossen et al., 1994; Hillen
and Berens, 1994; Urlinger et al., 2000). To establish a stably
transformed HeLa cell line, 2Apro gene was subcloned in pBI-G Tet
vector (Clontech, USA). The pBI-G Tet Vector contains the bidirec-
tional promoter Pbi-1, which is responsive to the tTA and rtTA
regulatory proteins in the Tet-Off and Tet-On systems, respectively.
Construction of pBI-G-2Apro
The pET22b plasmid containing 2Apro gene was used as the
template and PCR was performed. One pair of primers was used for
this part of preparation: F-2ak containing the PstI restriction site
(underlined) and Kozak sequence (5′-ATCCTGCAGACCACCATGGGCG-
CATTTGGACAAC-3′), and R-2a containing SalI restriction site (under-
lined) (5′-ACGGTCGACTCACTGTTCCATTGCATCATC-3′).
PCR was carried out by PFU polymerase under the following
conditions: initial denaturation at 94 °C for 5 min, 35 cycles (94°C for
1 min, 68 °C for 1 min, and 72 °C for 1 min), and a ﬁnal extension for
5 min at 72 °C. The PCR products digested by PstI/SalI were inserted
into the PstI/SalI restriction sites of digested/dephosphorylated pBI-G
vector (Clontech, USA) and ligated mixtures were transformed into
competent cells of E. coli DH5α using the electroporation method.
Preparation of a stable Tet-On HeLa cell line
Increasing concentrations (0, 50, 100, 200, 400, and 800 μg/ml) of
Geneticin (G418) (MP Biomedicals, USA) were tested on HeLa cell
cultures to ﬁnd a suitable concentration for developing the stable cell
line. HeLa cells were transfected with 5 μg of pWHE134 containing
neoR using the electroporation technique. Successfully transfected
colonies were selected based on their response to G418, whichresulted in massive cell death in ∼5 days. Two to four weeks following
treatment, G418-resistant HeLa cell colonies appeared. Large, healthy
colonies were selected and transferred to individual plates. HeLa Tet-
On Cells were grown and maintained in DMEM supplemented with
10% FBS and 150 μg/ml of G418 (GIBCO BRL, USA).
Development of a double-stable Tet-On HeLa cell line
A 60-mm-diameter plate seeded with 106 HeLa Tet-On cells was
cotransfected with 5 ng of pBI-G-2Apro encoding the CVB3 2Apro under
the control of the tet-responsive promoter, and 250 ng of linear
hygromycin marker (Clontech, USA). The transfection was carried out
by electroporation. Double-transfected HeLa cells were selected in the
presence of 200 μg/ml hygromycin B (Invitrogen, USA) and 150 μg/ml
of G418. Large and healthy-looking colonies were isolated and
expanded to individual plates. Cells were induced by 300 ng/ml
doxycycline for expression of 2Apro and 48 hours later hygromycin-
resistant cloneswere collected and total RNAwas extracted using RNX
plus solution according to the manufacturer's protocol (Cinnagen,
Iran). Complementary DNA synthesis reactions were performed using
1 μg of RNA and MMLV reverse transcriptase (Gibco BRL, Germany)
with oligo(dT)18 priming in a 20-ml reaction as described by
manufacturer. PCR was carried out using F-2ak and R-2a primers as
described before and β-actin (internal control) primers as follows:
forward primer; 5′-CACCACACCTTCTACAATGAGCTGCG-3′ and reverse
primer; 5′-TACTCCTGCTTGCTGATCCACATCTGC-3′. The PCR ampliﬁca-
tion was performed for 35 cycles. The cycling conditions for β-actin
were as follows: 94 °C for 30 s, 58.5 °C for 30 s, 72 °C for 1 min with a
ﬁnal extension at 72 °C for 5min. A suitable double-stable Tet-OnHeLa
cell line was frozen to ensure a renewable source for future use.
Treatment of cells with 16-mer peptide and measurement of cell viability
The established double stable Tet-on HeLa cell linewasmaintained
as monolayer in DMEM medium supplemented with 5% fetal bovine
serum, 200 μg/ml hygromycin B, and 150 μg/ml of G418. At the time
of experiment, transfected HeLa cells were induced by 300 ng/ml
doxycycline, then treated with increasing concentrations of peptide
(10–250 μg/ml), and cell viability was measured after 48 hours by the
conventional MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide] assay according to the manufacturer's protocol
(RDSystem, USA). Results were reported as the percentages of cell
viability, where the viability of the control group was arbitrary set as
100%.
Western blot analysis
To determine the activity of conditionally expressed viral 2Apro
protein in stably transfected Tet-on HeLa cells, cell lysates was
subjected to the sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE) and western blot analysis. Following various
treatments, cells were collected and cell lysates were prepared using
the lysis buffer containing 150 mM sodium chloride, 1.0% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS (sodium dodecyl sulphate), 50 mM
Tris pH 8.0. After centrifugation to remove cell debris, the lysates were
prepared using sample buffer (3% SDS, 5% β-mercaptoethanol, 10%
glycerol, 0.04% bromophenol blue, 60 mM Tris–HCl, pH 6.8), and then
loaded onto a 15% PAGE in a buffer containing 0.1% sodium dodecyl
sulfate. The proteins were transferred to a nitrocellulose transfer
membrane (Millipore, USA), and then were probed with speciﬁc
antibodies (Cell Signaling, USA). β-Actin protein was detected as a
control housekeeping protein to ensure equal protein loading in all
experiments. Protein bands were detected by chemiluminescence
using enhanced electrochemiluminescence (ECL) reagent (Amersham
Bioscience, USA) and autoradiography. Data analysis was done by
Labwork data analysis (Cambridge, UK).
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Sequence alignment was performed using the Psi-Blast sequence
alignment (Altschul et al., 1997). Protein tertiary structure predic-
tions were performed with the protein homology modeling Swiss
modeler server using the crystal structure of HRV2 2Apro (1z8r)
(Petersen et al., 1999) as a template. This program is completely
automated and is capable of generating energy minimized protein
models by satisfying spatial restrains on bond distance and dihedral
angles extracted from the template PDB ﬁle. The input for the
program modeler consisted of the aligned sequence of CVB3 and
HRV2 2Apro, a steering ﬁle that gives all the necessary commands to
the modeler and pdb ﬁle of the template. Many runs of modeler were
carried out to obtain the most plausible model. The program was
implemented using standard parameters and a database of protein
with known 3D structure. To ensure the reliability of the alignment
and modeling of variable surface loops, structural investigations on
the graphic screen using 3D visualization program Swiss pdb viewer
was performed. Docking study was performed with HEX 4.5 program
(Ritchie and Kemp, 2000). The substrate structure was estimated
with molecular dynamic (MD) simulation (Kohlbacher and Lenhof,
2000; Moll et al. 2006). A 10-ps short MD under AMBER force ﬁled
was sufﬁcient for a short peptide and BALL output used for docking
studies as ligand.
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